Prophylactic somatostatin can reduce incidence of post-ERCP pancreatitis: multicenter randomized controlled trial

Background and study aim: Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) remains the most common complication of ERCP. Somatostatin may inhibit pancreatic secretion and has been tested for PEP prophylaxis. However, the results of previous studies are inconsistent. The aim of the current study was to investigate whether somatostatin can reduce the incidence of PEP.

Patients and methods: The study was a multicenter, open-label, randomized controlled trial. A total of 908 patients with normal amylase levels who were undergoing ERCP were randomized to receive somatostatin 250 μg bolus injection before ERCP and 250 μg/hour intravenous infusion for 11 hours after ERCP (somatostatin group) or no somatostatin treatments (control group). The incidences of PEP and hyperamylasemia were compared in the two groups.

Results: The full analysis set included 900 patients (445 in the somatostatin group, 455 in the control group). PEP developed in 34 patients (7.5 %) in the control group (95 % confidence interval [CI] 5.4 % – 10.3 %) and in 18 patients (4.0 %) in the somatostatin group (95 %CI 2.6 % – 6.3 %; P = 0.03). Hyperamylasemia occurred in 46 patients (10.1 %) in the control group (95 %CI 7.7 % – 13.2 %) and in 27 patients (6.1 %) in the somatostatin group (95 %CI 4.2 % – 8.7 %; P = 0.03). No perforation or death occurred during the study.

Conclusions: This study showed that somatostatin was effective and safe for the prevention of PEP and hyperamylasemia in ERCP patients.

(ClinicalTrials.gov number, NCT01431781).

^* These authors are joint first authors.

^** These authors are joint corresponding authors.

• References

• 1 Anderson MA, Fisher L. ASGE Standards of Practice Committee et al. Complications of ERCP. Gastrointest Endosc 2012; 75: 467-473
• 2 Andriulli A, Loperfido S, Napolitano G et al. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol 2007; 102: 1781-1788
• 3 Wang P, Li ZS, Liu F et al. Risk factors for ERCP-related complications: a prospective multicenter study. Am J Gastroenterol 2009; 104: 31-40
• 4 Bai Y, Gao J, Zhang W et al. Meta-analysis: allopurinol in the prevention of postendoscopic retrograde cholangiopancreatography pancreatitis. Aliment Pharmacol Ther 2008; 28: 557-564
• 5 Bai Y, Gao J, Shi X et al. Prophylactic corticosteroids do not prevent post-ERCP pancreatitis: a meta-analysis of randomized controlled trials. Pancreatology 2008; 8: 504-509
• 6 Bai Y, Gao J, Zou DW et al. Prophylactic octreotide administration does not prevent post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized controlled trials. Pancreas 2008; 37: 241-246
• 7 Elmunzer BJ, Scheiman JM, Lehman GA et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med 2012; 366: 1414-1422
• 8 Choudhary A, Bechtold ML, Arif M et al. Pancreatic stents for prophylaxis against post-ERCP pancreatitis: a meta-analysis and systematic review. Gastrointest Endosc 2011; 73: 275-282
• 9 Freeman ML. Pancreatic stents for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Clin Gastroenterol Hepatol 2007; 5: 1354-1365
• 10 Bordas JM, Toledo-Pimentel V, Llach J et al. Effects of bolus somatostatin in preventing pancreatitis after endoscopic pancreatography: results of a randomized study. Gastrointest Endosc 1998; 47: 230-234
• 11 Lee KT, Lee DH, Yoo BM. The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis: a randomized, multicenter controlled trial. Pancreas 2008; 37: 445-448
• 12 Andriulli A, Clemente R, Solmi L et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc 2002; 56: 488-495
• 13 Andriulli A, Solmi L, Loperfido S et al. Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. Clin Gastroenterol Hepatol 2004; 2: 713-718
• 14 Omata F, Deshpande G, Tokuda Y et al. Meta-analysis: somatostatin or its long-acting analogue, octreotide, for prophylaxis against post-ERCP pancreatitis. J Gastroenterol 2010; 45: 885-895
• 15 Andriulli A, Leandro G, Federici T et al. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc 2007; 65: 624-632
• 16 Cotton PB, Lehman G, Vennes J et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991; 37: 383-393
• 17 Moffatt DC, Coté GA, Avula H et al. Risk factors for ERCP-related complications in patients with pancreas divisum: a retrospective study. Gastrointest Endosc 2011; 73: 963-970
• 18 Cotton PB, Garrow DA, Gallagher J et al. Risk factors for complications after ERCP: a multivariate analysis of 11,497 procedures over 12 years. Gastrointest Endosc 2009; 70: 80-88
• 19 Poon RT, Yeung C, Lo CM et al. Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial. Gastrointest Endosc 1999; 49: 593-598
• 20 Poon RT, Yeung C, Liu CL et al. Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomised controlled trial. Gut 2003; 52: 1768-1773
• 21 Testoni PA, Bagnolo F, Andriulli A et al. Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: results of a multicenter, randomized, controlled trial. Aliment Pharmacol Ther 2001; 15: 965-972
• 22 Rudin D, Kiss A, Wetz RV et al. Somatostatin and gabexate for post-endoscopic retrograde cholangiopancreatography pancreatitis prevention: meta-analysis of randomized placebo-controlled trials. J Gastroenterol Hepatol 2007; 22: 977-983
• 23 Arvanitidis D, Anagnostopoulos GK, Giannopoulos D et al. Can somatostatin prevent post-ERCP pancreatitis? Results of a randomized controlled trial. J Gastroenterol Hepatol 2004; 19: 278-282
• 24 Bordas JM, Toledo V, Mondelo F et al. Prevention of pancreatic reactions by bolus somatostatin administration in patients undergoing endoscopic retrograde cholangio-pancreatography and endoscopic sphincterotomy. Horm Res 1988; 29: 106-108
• 25 Testoni PA, Masci E, Bagnolo F et al. Endoscopic papillo-sphincterotomy: prevention of pancreatic reaction by somatostatin. Ital J Gastroenterol 1988; 20: 70-73
• 26 Saari A, Kivilaakso E, Schroder T. The influence of somatostatin on pancreatic irritation after pancreatography. An experimental and clinical study. Surg Res Comm 1988; 24: 271-278
• 27 Deschner K, Kalloo A, Collen M et al. Somatostatin: an evaluation of its utility as adjunctive medication for ERCP. Gastrointest Endosc 1989; 35: A149
• 28 Guelrud M, Mendoza S, Viera L et al. Somatostatin prevents acute pancreatitis after pancreatic duct sphincter hydrostatic balloon dilation in patients with idiopathic recurrent pancreatitis. Gastrointest Endosc 1991; 37: 44-47
• 29 Persson B, Slezak P, Efendic S et al. Can somatostatin prevent injection pancreatitis after ERCP?. Hepatogastroenterology 1992; 39: 259-261
• 30 Chan HH, Lai KH, Lin CK et al. Effect of somatostatin in the prevention of pancreatic complications after endoscopic retrograde cholangiopancreatography. J Chin Med Assoc 2008; 71: 605-609
• 31 Wang ZK, Yang YS, Cai FC et al. Is prophylactic somatostatin effective to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis or hyperamylasemia? A randomized, placebo-controlled pilot trial. Chin Med J (Engl) 2013; 126: 2403-2408
• 32 Benvenuti S, Zancanella L, Piazzi L et al. Prevention of post-ERCP pancreatitis with somatostatin versus gabexate mesilate: a randomized placebo-controlled multicenter study. Dig Liv Dis 2006; 38: S15
• 33 Altman DG. How large a sample?. In: Gore SM, Altman DG, , eds. Statistics in Practice. London: British Medical Association; 1982